IMV Executive Assistant
tel. (612) 624-1926
fax. (612) 625-1108
18-242 Moos Tower
515 Delaware St. SE
Minneapolis, MN 55455
University of Illinois
Focused on HIV infection. Also involved in treatment of HIV infected projects in resource-poor settings.
Henry K, Kitch D, Dube M, Zackin R, Parker RA al. C-reactive protein levels over time and cardiovascular risk in HIV-infected individuals suppressed on an indinavir-based regimen. AIDS 2004; 18: 2434-2437.
Henry K. Erice A. Balfour HH Jr. Schmeling M. Berthiaume J. Wallace K. Lymphocyte mitochondrial biomarkers in asymptomatic HIV-1-infected individuals treated with nucleoside reverse transcriptase inhibitors. [Letter] Aids. 16(18):2485-7, 2002 Dec 6.
Tebas P. Henry K. Mondy K. Deeks S. Valdez H. Cohen C. Powderly WG. Effect of prolonged discontinuation of successful antiretroviral therapy on CD4+ T cell decline in human immunodeficiency virus-infected patients: implications for intermittent therapeutic strategies. [Journal Article] Journal of Infectious Diseases. 186(6):851-4, 2002 Sep 15.
Fletcher CV. Anderson PL. Kakuda TN. Schacker TW. Henry K. Gross CR. Brundage RC. Concentration-controlled compared with conventional antiretroviral therapy for HIV infection. [Clinical Trial. Journal Article. Randomized Controlled Trial] Aids. 16(4):551-60, 2002 Mar 8.
Ross L. Henry K. Paar D. Salvato P. Shaefer M. Fisher R. Liao Q. St Clair M. Thymidine-analog and multi-nucleoside resistance mutations are observed in both zidovudine-naive and zidovudine-experienced subjects with viremia after treatment with stavudine-containing regimens. [Clinical Trial. Journal Article. Multicenter Study] Journal of Human Virology. 4(4):217-22, 2001 Jul-Aug.
Ross L. Scarsella A. Raffanti S. Henry K. Becker S. Fisher R. Liao Q. Hirani A. Graham N. St Clair M. Hernandez J. NZT40012 Study Team. Thymidine analog and multinucleoside resistance mutations are associated with decreased phenotypic susceptibility to stavudine in HIV type 1 isolated from zidovudine-naive patients experiencing viremia on stavudine-containing regimens. [Journal Article. Multicenter Study] AIDS Research & Human Retroviruses. 17(12):1107-15, 2001 Aug 10.
Erice A. Li W. Balfour HH Jr. Boies LR Jr. Melroe H. Henry K. Analysis of HIV-1 reverse transcriptase and protease sequences in paired plasma and lymphoid tissue specimens from HIV-1 infected individuals. [Journal Article] Aids. 15(7):831-6, 2001 May 4.
Verbiest W. Brown S. Cohen C. Conant M. Henry K. Hunt S. Sension M. Stein A. Stryker R. Thompson M. Schel P. Van Den Broeck R. Bloor S. Alcorn T. Van Houtte M. Larder B. Hertogs K. Prevalence of HIV-1 drug resistance in antiretroviral-naive patients: a prospective study. [Journal Article] Aids. 15(5):647-50, 2001 Mar 30.
Tebas P. Henry K. Nease R. Murphy R. Phair J. Powderly WG. Timing of antiretroviral therapy. Use of Markov modeling and decision analysis to evaluate the long-term implications of therapy. [Journal Article] Aids. 15(5):591-9, 2001 Mar 30.
Henry K. Risky behaviors with asymptomatic HIV infection?. [Journal Article] Postgraduate Medicine. 109(2):124, 2001 Feb.
Henry K. Wallace RJ. Bellman PC. Norris D. Fisher RL. Ross LL. Liao Q. Shaefer MS. TARGET Study Team. Twice-daily triple nucleoside intensification treatment with lamivudine-zidovudine plus abacavir sustains suppression of human immunodeficiency virus type 1: results of the TARGET Study. [Clinical Trial. Journal Article. Multicenter Study] Journal of Infectious Diseases. 183(4):571-8, 2001 Feb 15.
Kakuda TN. Page LM. Anderson PL. Henry K. Schacker TW. Rhame FS. Acosta EP. Brundage RC. Fletcher CV. Pharmacological basis for concentration-controlled therapy with zidovudine, lamivudine, and indinavir. [Clinical Trial. Journal Article. Randomized Controlled Trial] Antimicrobial Agents & Chemotherapy. 45(1):236-42, 2001 Jan.
Henry K. Hicks C. Antiretroviral rounds. Reason to be worried. [Newspaper Article] AIDS Clinical Care. 12(10):82-3, 2000 Oct.
Anderson PL. Noormohamed SE. Henry K. Brundage RC. Balfour HH Jr. Fletcher CV. Semen and serum pharmacokinetics of zidovudine and zidovudine-glucuronide in men with HIV-1 infection. [Clinical Trial. Journal Article] Pharmacotherapy. 20(8):917-22, 2000 Aug.
Henry K. The case for more cautious, patient-focused antiretroviral therapy.[comment]. [Review] [75 refs] [Journal Article. Review. Review, Tutorial] Annals of Internal Medicine. 132(4):306-11, 2000 Feb 15.
Staudinger R. Henry K. Remission of HIV myelopathy after highly active antiretroviral therapy.[comment]. [Journal Article] Neurology. 54(1):267-8, 2000 Jan 11.
Niubo J. Li W. Henry K. Erice A. Recovery and analysis of human immunodeficiency virus type 1 (HIV) RNA sequences from plasma samples with low HIV RNA levels. [Journal Article] Journal of Clinical Microbiology. 38(1):309-12, 2000 Jan.
Henry K. Craven D. Keeping options open. [Newspaper Article] AIDS Clinical Care. 11(1):4-5, 1999 Jan.
Price RW. Yiannoutsos CT. Clifford DB. Zaborski L. Tselis A. Sidtis JJ. Cohen B. Hall CD. Erice A. Henry K. Neurological outcomes in late HIV infection: adverse impact of neurological impairment on survival and protective effect of antiviral therapy. AIDS Clinical Trial Group and Neurological AIDS Research Consortium study team. [Clinical Trial. Journal Article. Multicenter Study. Randomized Controlled Trial] Aids. 13(13):1677-85, 1999 Sep 10.
Melroe NH. Kopaczewski J. Henry K. Huebsch J. Intervention for hyperlipidemia associated with protease inhibitors.[erratum appears in J Assoc Nurses AIDS Care 1999 Sep-Oct;10(5):109]. [Clinical Trial. Journal Article] Journal of the Association of Nurses in AIDS Care. 10(4):55-69, 1999 Jul-Aug.
Acosta EP. Henry K. Baken L. Page LM. Fletcher CV. Indinavir concentrations and antiviral effect. [Journal Article] Pharmacotherapy. 19(6):708-12, 1999 Jun.
Zhang ZQ. Schuler T. Cavert W. Notermans DW. Gebhard K. Henry K. Havlir DV. Gunthard HF. Wong JK. Little S. Feinberg MB. Polis MA. Schrager LK. Schacker TW. Richman DD. Corey L. Danner SA. Haase AT. Reversibility of the pathological changes in the follicular dendritic cell network with treatment of HIV-1 infection. [Journal Article] Proceedings of the National Academy of Sciences of the United States of America. 96(9):5169-72, 1999 Apr 27.
Tebas P. Patick AK. Kane EM. Klebert MK. Simpson JH. Erice A. Powderly WG. Henry K. Virologic responses to a ritonavir--saquinavir-containing regimen in patients who had previously failed nelfinavir.[comment]. [Clinical Trial. Journal Article] Aids. 13(2):F23-8, 1999 Feb 4.
Melroe NH. Kopaczewski J. Henry K. Huebsch J. Lipid abnormalities associated with protease inhibitors. [Journal Article] Journal of the Association of Nurses in AIDS Care. 10(2):22-30, 1999 Mar-Apr.
Henry K. Affordable drug offers hope for preventing mother-to-child transmission of HIV. [Journal Article] Impact on HIV. 1(2):15-21, 1999 Sep.
Henry K. Systematic behavioral surveys recommended for next generation of HIV surveillance. [Journal Article] Impact on HIV. 1(2):29-33, 1999 Sep.
Cotton D. Henry K. The perils of progress. [Newspaper Article] AIDS Clinical Care. 11(10):82-3, 1999 Oct.
Feinberg J. Henry K. A patient with no options?. [Newspaper Article] AIDS Clinical Care. 10(8):61, 63-4, 1998 Aug.
Henry K. Erice A. Tierney C. Balfour HH Jr. Fischl MA. Kmack A. Liou SH. Kenton A. Hirsch MS. Phair J. Martinez A. Kahn JO. A randomized, controlled, double-blind study comparing the survival benefit of four different reverse transcriptase inhibitor therapies (three-drug, two-drug, and alternating drug) for the treatment of advanced AIDS. AIDS Clinical Trial Group 193A Study Team. [Clinical Trial. Journal Article. Multicenter Study. Randomized Controlled Trial] Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology. 19(4):339-49, 1998 Dec 1.
Fletcher CV. Acosta EP. Henry K. Page LM. Gross CR. Kawle SP. Remmel RP. Erice A. Balfour HH Jr. Concentration-controlled zidovudine therapy. [Clinical Trial. Journal Article. Randomized Controlled Trial] Clinical Pharmacology & Therapeutics. 64(3):331-8, 1998 Sep.
Henry K. Melroe H. Huebsch J. Hermundson J. Levine C. Swensen L. Daley J. Severe premature coronary artery disease with protease inhibitors.[comment]. [Letter] Lancet. 351(9112):1328, 1998 May 2.
Zhang ZQ. Notermans DW. Sedgewick G. Cavert W. Wietgrefe S. Zupancic M. Gebhard K. Henry K. Boies L. Chen Z. Jenkins M. Mills R. McDade H. Goodwin C. Schuwirth CM. Danner SA. Haase AT. Kinetics of CD4+ T cell repopulation of lymphoid tissues after treatment of HIV-1 infection. [Journal Article] Proceedings of the National Academy of Sciences of the United States of America. 95(3):1154-9, 1998 Feb 3.
Henry K. Long-term strategies: should some patients wait to start protease inhibitors? Interview with Keith Henry, M.D. Interview by John S. James. [Interview. Newspaper Article] AIDS Treatment News. (No 281):1, 3-6, 1997 Oct 17.
Henry K. Stiffman M. Feldman J. Antiretroviral therapy for HIV infection. Heartening successes mixed with continuing challenges. [Review] [12 refs] [Journal Article. Review. Review, Tutorial] Postgraduate Medicine. 102(4):100-7, 111-3, 119-20, 1997 Oct.
Henry K. HIV/AIDS. [Journal Article] Postgraduate Medicine. 102(4):97-8, 1997 Oct.
Li Q. Gebhard K. Schacker T. Henry K. Haase AT. The relationship between tumor necrosis factor and human immunodeficiency virus gene expression in lymphoid tissue. [Journal Article] Journal of Virology. 71(9):7080-2, 1997 Sep.
Fletcher CV. Goodroad BK. Cummins LM. Henry K. Balfour HH Jr. Rhame FS. Pharmacokinetics of hyperimmune anti-human immunodeficiency virus immunoglobulin in persons with AIDS. [Clinical Trial. Journal Article] Antimicrobial Agents & Chemotherapy. 41(7):1571-4, 1997 Jul.
Acosta EP. Henry K. Page LM. Erice A. Balfour HH Jr. Fletcher CV. Pharmacokinetics and safety of concentration-controlled oral zidovudine therapy. [Clinical Trial. Journal Article. Randomized Controlled Trial] Pharmacotherapy. 17(3):424-30, 1997 May-Jun.
Cavert W. Notermans DW. Staskus K. Wietgrefe SW. Zupancic M. Gebhard K. Henry K. Zhang ZQ. Mills R. McDade H. Schuwirth CM. Goudsmit J. Danner SA. Haase AT. Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection.[comment][erratum appears in Science 1997 May 30;276(5317):1321]. [Clinical Trial. Journal Article. Randomized Controlled Trial] Science. 276(5314):960-4, 1997 May 9.
Haase AT. Henry K. Zupancic M. Sedgewick G. Faust RA. Melroe H. Cavert W. Gebhard K. Staskus K. Zhang ZQ. Dailey PJ. Balfour HH Jr. Erice A. Perelson AS. Quantitative image analysis of HIV-1 infection in lymphoid tissue. [Journal Article] Science. 274(5289):985-9, 1996 Nov 8.
Faust RA. Henry K. Dailey P. Melroe H. Sullivan C. Erice A. Haase AT. Boies LR Jr. Outpatient biopsies of the palatine tonsil: access to lymphoid tissue for assessment of human immunodeficiency virus RNA titers. [Journal Article] Otolaryngology - Head & Neck Surgery. 114(4):593-8, 1996 Apr.
Henry K. Evaluating HIV / AIDS prevention programs. Meeting the challenge. [Journal Article] Aids Captions. 3(2):29-34, 1996 Jul.
'Wisc-e-sota', a Joint UMN-UW Virology Training Grant Symposium was first held on Friday, Sepbember 20th, 2013 at the Uniiversity of Wisconsin-La Crosse, Cartwright Center. This was the inaugural collaborative symposium of the NIH T32-supported virology training programs at the University of Wisconsin-Madison and the University of Minnesota-Twin Cities. Talks and poster sessions were presented by students, postdocs and faculty. The second UMN-UW Virology Training Grant Symposium will be held in the Fall 2014. Details to follow.
The 2014 IMV Symposium will be held on May 12, 2014 and Mark Denison (Vanderbilt) and Bert Semler (UC-Irvine) will be the Keynote Speakers. Click on the link below to register and submit abstracts.
Read about bacteriophage phi 29 and why it matters.
Explore nearly a century's worth of discovery in the field of virology at the University of Minnesota.
"This Week in Virology" from professor Vincent Racaniello.